1836 U.S. Patent Office fire

Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs

Retrieved on: 
Monday, August 28, 2023

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that the United States Patent and Trademark Office issued U.S. Patent No.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that the United States Patent and Trademark Office issued U.S. Patent No.
  • 11,707,441, titled “C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using,” pertaining to the Company’s lead candidate EB-373, a psilocin prodrug being developed for the treatment of anxiety disorder.
  • This new patent, issued July 25, 2023, provides Enveric with intellectual property rights for compositions and methods for tryptamine-derived prodrugs utilizing C4-substituted tryptamine derivatives and C4-carbonothiate-substituted tryptamine derivatives.
  • Enveric’s lead product candidate, EB-373, is a new chemical entity (NCE) psilocin prodrug being developed for the treatment of anxiety disorder.

ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents

Retrieved on: 
Wednesday, August 23, 2023

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, one in the U.S. and two in Europe.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, one in the U.S. and two in Europe.
  • ENDRA’s intellectual property portfolio now includes 67 issued patents worldwide, providing protection for the TAEUS® system with its novel hybrid ultrasound and thermoacoustic imaging technology.
  • The following three patents strengthening the TAEUS system’s proprietary position were issued:
    U.S. Patent No.
  • 11730374, titled “Radio Frequency Applicator for a Thermoacoustic Imaging System,” relates to a novel radio frequency applicator with an integrated wedge.

Altria Seeks Importation Ban of JUUL E-Vapor Products; Files Patent Infringement Actions Against JUUL Labs

Retrieved on: 
Tuesday, August 22, 2023

Altria Group, Inc. (NYSE: MO) today announces that its subsidiary, NJOY, has filed a complaint against JUUL Labs, Inc. (JUUL) with the U.S. International Trade Commission (ITC).

Key Points: 
  • Altria Group, Inc. (NYSE: MO) today announces that its subsidiary, NJOY, has filed a complaint against JUUL Labs, Inc. (JUUL) with the U.S. International Trade Commission (ITC).
  • The complaint seeks a ban on the importation and sale of certain JUUL e-vapor products, including its currently marketed JUUL device and JUULpods.
  • “Protecting our intellectual property is critical to achieving our Vision,” said Murray Garnick, Executive Vice President and General Counsel.
  • NJOY acquired the Asserted Patents from Fuma International, LLC (Fuma) concurrently with the settlement of a patent infringement lawsuit filed against us by Fuma.

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Friday, August 11, 2023

MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2023.

Key Points: 
  • MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2023.
  • On August 10, 2023 the Company obtained construction permits required to begin the buildout of its new headquarters.
  • Second Quarter 2023 Financial Results:
    Revenues: Revenues for the quarter ended June 30, 2022 and 2023 were $454,000 and $622,807, respectively.
  • Net loss: Net loss for the quarter ended June 30, 2022 and 2023 was $3.5 million and $4.3 million, respectively, an increase of $793,859, or 23%.

Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results

Retrieved on: 
Tuesday, August 8, 2023

NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended June 30, 2023.

Key Points: 
  • Company expects to announce topline results from this study in the second half of 2023.
  • Alzheimer’s disease: Full data ANAVEX®2-73-AD-004, including newly available preliminary results of surrogate biomarkers of pivotal Phase 2b/3 clinical trial.
  • General and administrative expenses for the quarter of $3.2 million compared to $3.2 million for the comparable quarter of fiscal 2022.
  • Research and development expenses for the quarter of $10.3 million compared to $9.3 million for the comparable quarter of fiscal 2022.

Sea & Flour Awarded Patent for Systems and Methods for Processing Seaweed Used in Commercial Baking

Retrieved on: 
Tuesday, August 8, 2023

PHILADELPHIA, Aug. 8, 2023 /PRNewswire/ -- Sea & Flour, the first company to integrate seaweed into the commercial baking process, announced today it has been awarded a patent for systems and methods for processing seaweed. The patent (U.S. Patent No. 11,717,010) pertains to the process of cold washing, processing and granulating seaweed for use in breads and other related products. These processes help ensure that seaweed can be successfully incorporated into high volume baking while delivering the exceptional flavor and the nutritional benefits that come from the sea.

Key Points: 
  • Sea & Flour's first-of-its-kind line of bread products features seaweed as a primary ingredient, increasing protein content and lowering sodium compared to some standard bread loaves
    PHILADELPHIA, Aug. 8, 2023 /PRNewswire/ -- Sea & Flour , the first company to integrate seaweed into the commercial baking process, announced today it has been awarded a patent for systems and methods for processing seaweed.
  • 11,717,010) pertains to the process of cold washing, processing and granulating seaweed for use in breads and other related products.
  • These processes help ensure that seaweed can be successfully incorporated into high volume baking while delivering the exceptional flavor and the nutritional benefits that come from the sea.
  • "Being awarded this patent is recognition of the uniqueness of our approach and the methods we developed and perfected over several years," said Arlin Wasserman, Co-founder and CEO of Sea & Flour.

Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology

Retrieved on: 
Tuesday, August 1, 2023

TORONTO and HOUSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the issuance of U.S. Patent No.

Key Points: 
  • TORONTO and HOUSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the issuance of U.S. Patent No.
  • The patent further strengthens Medicenna's intellectual property around its BiSKIT™ (Bifunctional SuperKine for ImmunoTherapy) platform.
  • The patent protects a new method for enhancing fitness, survival and proliferation of cancer killing effector T cells and NK cells.
  • The Company’s Superkine patent estate is currently comprised of 56 granted and 61 pending patent applications.

Itential Announces Issuance of Two New U.S. Patents for Its Network Integration, Automation, & Orchestration Technology

Retrieved on: 
Tuesday, August 1, 2023

ATLANTA, Aug.1, 2023 /PRNewswire-PRWeb/ -- Itential, the leading cloud-based network automation and orchestration platform, announced today that the United States Patent and Trademark Office (USPTO) has issued two patents related to aspects of its API integration, data federation, and transformation capabilities for hybrid multi-cloud network automation. Today's news further solidifies Itential's leadership in driving innovation for a more integrated, programmable, network-first automation ecosystem.

Key Points: 
  • The Itential Automation Platform is built on a flexible, dynamic integration model for network automation.
  • Itential provides out-of-the-box, no-cost integrations to all network and IT systems so network teams can easily build end-to-end automations across their entire network infrastructure.
  • Itential's API federation capabilities enable users to leverage a single aggregated API for the entire network, simplifying automation across multiple network technologies.
  • "These patents are critical building blocks of our current portfolio capabilities and future product roadmap," said Chris Wade, Co-Founder and CTO of Itential.

Burns & Levinson Partner Shawn Foley Named a 2023 Go To Intellectual Property Lawyer by Mass Lawyers Weekly

Retrieved on: 
Tuesday, July 25, 2023

BOSTON, July 25, 2023 /PRNewswire/ -- Burns & Levinson partner Shawn Foley , who co-chairs the firm's Life Sciences Group, has been named a 2023 Go To Intellectual Property Lawyer by Mass Lawyers Weekly.

Key Points: 
  • BOSTON, July 25, 2023 /PRNewswire/ -- Burns & Levinson partner Shawn Foley , who co-chairs the firm's Life Sciences Group, has been named a 2023 Go To Intellectual Property Lawyer by Mass Lawyers Weekly.
  • The list recognizes the top lawyers in the region who are leaders in their field with a long history of success.
  • Foley has more than 30 years of experience designing and implementing global patent strategies for life sciences companies.
  • He also routinely conducts due diligence and freedom to operate studies for Fortune 500 companies.

U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation

Retrieved on: 
Monday, July 24, 2023

Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPR

Key Points: 
  • Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPR
    MORRISVILLE, N.C., July 24, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the Court of Appeals for the Federal Circuit (Federal Circuit) has affirmed all rulings by the United States District Court for the District of Delaware (District Court) in litigation filed by United Therapeutics (UTHR) under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman litigation), which alleged that Liquidia’s YUTREPIA™ (treprostinil) inhalation powder infringes U.S. Patent No.
  • 10,716,793 (‘793 Patent).
  • UTHR has appealed the PTAB’s decision to the Federal Circuit and briefing should be completed in the fourth quarter of 2023.
  • If the Federal Circuit upholds the PTAB decision, then Liquidia will seek final regulatory approval for YUTREPIA.